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The increasing number of RNA crystal structures
enables a structure-based approach to the discovery
of new RNA-binding ligands. To develop the poorly
explored area of RNA-ligand docking, we have con-
ducted a virtual screening exercise for a purine ribos-
witch to probe the strengths and weaknesses of
RNA-ligand docking. Using a standard protein-ligand
docking program with only minor modifications, four
new ligands with binding affinities in the micromolar
range were identified, including two compounds
based on molecular scaffolds not resembling known
ligands. RNA-ligand docking performed comparably
to protein-ligand docking indicating that this
approach is a promising option to explore the wealth
of RNA structures for structure-based ligand design.
INTRODUCTION
Target-driven drug discovery efforts have focused traditionally
on modifying protein functions. By contrast, RNA has remained
largely unexplored as a drug target. Despite its polyelectrolyte
character, RNA can adopt intricate three-dimensional structures
that are essential for function. The folded structure enables
RNA to bind small molecules with high affinity and selectivity
and even to catalyze chemical reactions (Holbrook, 2005). RNA
plays a central role in almost every genetic process of the cell,
and is therefore a potential drug target (Hermann, 2000; Blount
and Breaker, 2006; Thomas and Hergenrother, 2008). Indeed,
many long-known antibiotics bind to the 16S ribosomal RNA
component of the bacterial ribosome (Moazed and Noller,
1987). More recently, it was discovered that also sections of
some mRNAs (termed riboswitches) are targets for antibiotics
(Blount and Breaker, 2006; Kim et al., 2009; Lee et al., 2009;
Ott et al., 2009; Mulhbacher et al., 2010). The increasing number
of RNA crystal structures enables a structure-based approach to
the discovery of novel RNA-binding ligands (Franceschi and
Duffy, 2006; Schwalbe et al., 2007; Serganov, 2010). However,
whereas structure-based techniques are routinely used in the
protein field, their application in the RNA field is still in its infancy
(Fulle and Gohlke, 2010).324 Chemistry & Biology 18, 324–335, March 25, 2011 ª2011 ElsevieOne way to exploit the target structure for ligand binding is
fragment screening, which has recently been applied to RNA
targets (Bodoor et al., 2009; Chen et al., 2010). Molecular
docking is another key method in the area of structure-based
design (Klebe, 2006). Docking predicts the preferred orientation
of a small molecule in binding to a receptor to form a stable
complex. Docking can also be used for virtual screening of
databases containing millions of molecules for potential ligands.
In that case, each database entry is sequentially docked into
the binding site and scored for its fit, resulting in a score-ranked
list.
There are two strategies for RNA-ligand docking: (1) to
adopt methods and scoring functions originally developed for
protein-ligand docking (Lind et al., 2002; Detering and Varani,
2004; Kang et al., 2004; Moitessier et al., 2006; Park et al.,
2008; Lang et al., 2009; Li et al., 2010b) and (2) to develop entirely
new scoring functions or docking algorithms (Morley and
Afshar, 2004; Barbault et al., 2006; Pfeffer and Gohlke, 2007;
Guilbert and James, 2008). What all of these RNA docking
studies have in common is that the vast majority of the investi-
gated targets are rather complex including large and flexible
ligands, water-mediated interactions, and flexible receptors. All
these approaches are still challenging for the more-explored
protein-ligand docking (Klebe, 2006) and make it difficult to
disentangle these effects from issues specific to RNA-ligand
docking. In order to develop this field, we therefore sought
a model system that would be both experimentally and compu-
tationally tractable, and that would facilitate the dissection of
various contributions to ligand binding energies to guide
improvement of computational methods. In this study we have
selected the Bacillus subtilis xpt-pbuX guanine riboswitch
carrying a C74U mutation (called GRA) (Gilbert et al., 2006b) as
such a model system, and we demonstrate its potential for
probing RNA-ligand docking.
Riboswitches are cis-acting gene regulatory elements that are
mostly found in bacteria (Lee et al., 2009). They are located in
the 50 untranslated region (UTR) of mRNAs and consist of an
aptamer domain that binds the ligand, and an expression
platform that controls the expression of the downstream gene.
The RNA can adopt one of several alternative conformations, the
relative stability of which is determined by the binding of the
ligand to the aptamer domain. Binding of the ligand directs
folding of downstream elements in the expression platform
that influence expression. Thus, regulation of gene expressionr Ltd All rights reserved
Figure 1. Binding Sites of the Adenine and the B. subtilis xpt-pbuX
Guanine Riboswitch C74U Mutant
(A) Binding pocket of the V. vulnificus AR bound to adenine (green carbon
atoms; water molecule close to ligand as green sphere) superimposed with
GRA (blue carbon atoms, water molecule close to bound ligand drawn as red
sphere, ligand removed for clarity). The solvent accessible surface is shown in
blue. Hydrogen bonds are marked as dashed lines. The nucleotides forming
the binding pockets are fully conserved between AR and GRA and adopt the
same conformation in the ligand bound structure.
(B) Crystallographically determined binding mode of 15 together with Fo-Fc
map (contoured on 3.0 s) which was calculated by omitting the ligand from the
final model. Putative hydrogen bonds are marked as dashed lines. The water
molecule W364 from 2G9C is displaced by the N6-methyl group of the ligand.
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the structure of the RNA. Crystal structures of over ten
riboswitches have been determined, making this class of RNA
amenable for structure-based drug design (Schwalbe et al.,
2007; Serganov, 2010).Chemistry & Biology 18, 3The adenine-binding riboswitch (AR) and the related GRA
are among the best characterized riboswitches. The GRA was
derived by a point mutation from the guanine riboswitch
(C74U) (Gilbert et al., 2006b). As a result, the specificity of the
guanine riboswitch was altered to be adenine responsive, thus
generating a new adenine riboswitch (GRA). Crystal structures
have been determined for the aptamer domains of Vibrio
vulnificus AR and B. subtilis GRA (Serganov et al., 2004; Gilbert
et al., 2006a). The bases of both aptamer domains that form the
binding site are fully conserved and adopt the same conforma-
tion in the ligand- bound structure (Figure 1A) (Serganov et al.,
2004). The adenine binding site is rather small (108 A˚3) and
98% shielded from bulk solvent. In the available crystal struc-
tures, all ligands are bound in a similar orientation, forming
multiple hydrogen bonds with the nucleotides U22, U51, as
well as U74, and pi-stacking interactions with U47, A52, A21,
and U75. A conserved water molecule located toward the
opening of the pocket forms an additional hydrogen bond to
the ligands. Binding studies with both AR and GRA have been
carried out and a range of ligands as well as compounds not
binding to these riboswitches (here referred to as decoys) have
been identified (Mandal and Breaker, 2004; Gilbert et al.,
2006a, 2009).
The program DOCK 3.5.54 was applied to dock ligands into
the riboswitch structure (Lorber and Shoichet, 1998; Wei et al.,
2002). DOCK 3.5.54 uses a force-field-based scoring function
to estimate the binding energy (E) that accounts for van der
Waals (Evdw) and electrostatic energy (Eelec) and corrects for
the desolvation energy of the ligands (DGsolv) when transferred
from aqueous solution into the binding site (Equation 1):
E=Eelec +Evdw +DGsolv: (1)
Unlike regression- or knowledge-based scoring functions,
force-field-based scoring function are derived from physico-
chemical theory, and therefore do not require a training set of
protein- or RNA-ligand complexes together with affinity data
for parameterization (Gohlke and Klebe, 2001). Thus, the only
modification required to adapt the DOCK 3.5.54 scoring function
for RNA-ligand docking was to use RNA-specific parameters to
calculate Evdw and Eelec. Docking was evaluated retrospectively
using previously published data in terms of bindingmode predic-
tion, separation of known ligands and decoys, and enrichment of
ligands among a database of similar compounds. For prospec-
tive predictions, high scoring compounds from a database
screen were purchased and tested for ligand binding. Crystal
structure complexes with selected ligands were determined to
test the predicted binding modes. The implications of the results
in respect to advancing RNA-ligand docking, molecular docking
in general, and molecular recognition properties of riboswitches
which bind adenine with high affinity are discussed.RESULTS
Retrospective Docking Results
Binding Mode Prediction
At the outset of the study, three crystal structures of riboswitches
capable of binding adenine with high affinity were known:
V. vulnificus AR in complex with adenine (4 in Table 1) and24–335, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 325
Table 1. Test Set of Experimentally Confirmed Ligands and
Decoys Taken from the Literature
Compound # Rank
Score [kJ/mol]
(Rmsda [A˚]) Structureb KD [mM]
1 1
34.18
(0.24)
0.01c
2 2 33.97 20d
3 3 32.00 0.3c
4 4 31.85(0.34) 0.3c
5 5 31.81(0.13) 20d
6 6 30.44 NAc,e
7 7 29.90 30c
8 8 26.71 20d
9 9 25.11 NAc
10 10 23.24 NAc
Table 1. Continued
Compound # Rank
Score [kJ/mol]
(Rmsda [A˚]) Structureb KD [mM]
11 11 21.36 NAf
12 12 20.03 NAc
13 13 18.99 NAc
14 14 18.33 NAc
15 15 17.49 100c
16 16 15.97 NAc
17 17 14.48 NAc
18 18 14.17 NAc
19 19 11.97 NAg
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Table 1. Continued
Compound # Rank
Score [kJ/mol]
(Rmsda [A˚]) Structureb KD [mM]
20 20 9.93 NAg
21 21 8.50 NAg
22 22 7.01 NAc
23 23 15. 92 NAc
aBetween crystallographically determined binding mode and highest
scoring binding mode.
bHighest scoring database representation (tautomer, protonation state).
cMandal and Breaker (2004).
dGilbert et al. (2006a).
eNot applicable.
f Gilbert et al. (2009).
g Batey, unpublished data.
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triamino-pyrimidine (5) (Serganov et al., 2004; Gilbert et al.,
2006a, 2006b). The binding sites of AR and GRA are fully
conserved and the conformation of the binding site residues in
all crystal structures were the same within experimental error
(rmsd <0.3 A˚, Figure 1A). All structures included a water mole-
cule hydrogen bonded to the ligand. This water molecule was
therefore retained for all docking calculations. TheGRA structure
in complex with pyrimidine-2,4,6-triamine, which has the highest
resolution among the three riboswitch structures (1.7 A˚), was
chosen as receptor for docking. Hydrogen atoms were added
and their geometry optimized. Partial charges for RNA atoms
were obtained from the AMBER99 force field (Wang et al.,
2000) except that the charge of the phosphate oxygen atoms
was increased to yield a net charge of zero per nucleotide as
done previously (Detering and Varani, 2004; Moitessier et al.,
2006). Subsequently, all three ligands for which binding modes
were known were docked into the receptor using DOCK
3.5.54. Comparison of the predicted binding modes with those
determined crystallographically revealed that each was close
to native (rmsd <0.34 A˚, Table 1).Chemistry & Biology 18, 3Separation of Known Ligands and Decoys
Next, we tested whether a separation of decoys and ligands
could be achieved by docking. A test set of compounds with
known binding properties for AR and GRA was compiled
(Mandal and Breaker, 2004; Gilbert et al., 2006a). For three
ligands it was shown that they bind with comparable binding
affinities to both riboswitches (Gilbert et al., 2006a). We therefore
assumed that binding data for these riboswitches was transfer-
able and included ligands and decoys determined with either
riboswitch variant in the test. Conflicting results were reported
for guanine. Whereas for AR a binding affinity of >10 mM was
determined, no binding to GRA could be observed for this
compound (Mandal and Breaker, 2004; Gilbert et al., 2009).
The last result is in agreement with the established pharmaco-
phore for AR ligands (Mandal and Breaker, 2004). Therefore,
guanine was classified as decoy for this study. In total, the test
set contained 23 compounds, 8 ligands, and 15 decoys (Table 1).
The binding affinities of the ligands ranged from 0.01 to 100 mM.
For the decoys, no bindingwas detected up to 300 mMexcept for
guanine which was tested up to its solubility limit.
All compounds in the test set were docked into the GRA
binding site and sorted by their score (Table 1). A clear separa-
tion of ligands and decoys was obtained. Seven out of the eight
top-scoring compounds were true ligands. The probability to
achieve such a distribution by chance is only 0.02%. All eight
compounds with the lowest score were decoys.
The highest scoring decoy, 8-azaadenine (6), ranked sixth. In
the docking database, this compound was stored as a neutral
molecule. However, the pKa of the hydrogen atom bearing N1
atom in this compound was calculated to be 7.6. Accordingly
the compound is predominantly deprotonated under assay
conditions (pH 8.3). When the negatively charged species was
docked into the receptor, this compound received a score of
only +15.52 kJ/mol, ranking at 22.
N6-methyladenine (15) was the weakest ligand in the test set.
It obtained the least favorable score of all ligands, even lower
than many of the decoys (Table 1). However, 15 is also the
largest molecule of all binders and thus requires the largest
amount of space in the binding pocket. In the predicted binding
mode, the ligand adopts a conformation distinct from adenine
with the N6-methylamino group pointing into the cleft between
U51 and U74 resulting in unfavorable interactions (not shown).
In order to adopt a similar bindingmode as adenine the structural
water molecule W364 would have to be expelled from the
receptor (Figure 1A). This prompted us to determine the crystal
structure of the N6-methyladenine-riboswitch complex (Table 2).
The crystallographic analysis revealed that 15 indeed expels
W364 from the binding site and adopts a similar binding mode
as adenine (Figure 1B). When docked into the receptor without
the water molecule present the correct binding mode was ob-
tained (rmsd = 0.5A˚). With a score of 32.83 kJ/mol the ligand
would rank third in the database screen.
The three compounds in the test set with submicromolar
binding constants ranked among the top five highest scoring
compounds (Table 1). Yet despite this, no strong correlation
between binding affinities and scores was found (Pearson corre-
lation coefficient r = 0.64). This did also not improve when the
corrected scores for 6 and 15 were taken into consideration
(r = 0.68).24–335, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 327
Table 2. Crystallographic Data and Refinement Statistics of GRA-Ligand Complexes
Details of Data Collection
Ligand Complex 14 24 26 27
PDB Code 2xo1 2nxw 2nxz 2xo0
Space Group C2 C2 C2 C2
Unit Cell Dimensions (A˚) a = 132.762 a = 135.895 a = 132.165 a = 130.923
b = 35.180 b = 35.380 b = 35.068 b = 34.940
c = 41.763 c = 42.197 c = 41.778 c = 42.074
b = 90.51 b = 92.20 b = 92.06 b = 92.11
Resolution Range (A˚) 20–1.6 (1.66–1.6) 67.88–1.5 (1.55–1.5) 60.08–1.6 (1.66–1.6) 65.5–1.7 (1.76–1.7)
Observations 72,587 80,100 93,460 62,872
Unique Observations 25,098 30,250 25,334 21,077
Completeness (%) 96.5 (91.0) 93.1 (97.9) 98.5 (98.1) 96.8 (93.5)
<I/s(I) > 20.6 (2.7) 18.0 (2.3) 30.2 (2.9) 26.8 (3.1)
Rmerge
a (%) 5.3 (25.8) 6.2 (38.5) 4.4 (39.8) 5.2 (39.1)
Refinement Statistics
Resolution Range (A˚) 20–1.6 67.88–1.5 66.08–1.6 65.51–1.7
R-factorb % (Rwork/Rfree) 19.5/21.1 21.4/24.4 19.8/23.4 21.6/27.1
Number of atomsc 1364/11/226/56 1366/10/329/54 1382/9/216/52 1363/16/151/55
Mean B-factord (A˚2) 22.7/18.3/29.0/25.8 21.7/22.1/29.0/23.8 24.9/22.7/29.2/27.9 29.6/26.3/30.2/32.7
RMS bond length deviation (A˚) 0.008 0.009 0.009 0.013
RMS bond angle deviation () 1.508 1.683 1.546 1.973
Values in brackets are for the highest resolution shell.
a Rmerge =
PjI – < I > j /P < I >.
b R-factor =
P
Fo – Fcj /
P
Fo.
c Number of atoms.
dMean B-factors for RNA, ligands, water molecules, and other atoms, respectively.
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of Similar Compounds
In the final retrospective experiment, we tested how well RNA-
ligand docking can enrich the known ligands among the top
scoring compounds when a large database was docked into
the GRA binding site. For that purpose, we assembled a data-
base with commercially available compounds. To avoid artificial
enrichment (Verdonk et al., 2004) only compounds resembling
the ligands and decoys in the test set were selected for this data-
base. Our in-house database containing commercially available
compounds (Brenk et al., 2008) was filtered for compounds con-
taining up to 18 nonhydrogen atoms, one or two ring systems, at
least one hydrogen bond donor and acceptor and a net charge
between1 and +2. In addition, the compounds had to be small
enough to fit into the GRA binding site without causing a steric
clash. The final database contained 2592 unique compounds.
The compounds in the database together with those of the test
set were docked into the GRA binding site and ordered by score.
Based on this list the true positive rate (fraction of known
compounds, ligands or decoys) was plotted against the false
positive rate (fraction of unassigned database compounds) to
obtain a receiver operation characteristic (ROC) curve (Figure 2)
(Jain, 2004). The area under the curve (AUC) of a ROC curve is
a measure of the test accuracy. A perfect prediction would be
indicated by an AUC of 1.0 while random prediction would result
in an AUC of 0.5. For the ligands an AUC value of 0.98 was
obtained and for the decoys a value of 0.75. Thus, close to328 Chemistry & Biology 18, 324–335, March 25, 2011 ª2011 Elsevieperfect enrichment of the ligands was achieved. The decoys
were also enriched compared to random. The reason for this is
that the decoys were selected on a rational basis to resemble
known ligands and such have at least some of the properties
required to bind into the GRA pocket (Mandal and Breaker,
2004).
Prospective Results
Encouraged by the retrospective docking results we then per-
formed more rigorous prospective tests. We selected a number
of compounds for experimental characterization from among the
top scoring hits obtained by docking the database of commer-
cially available compounds. The selected compounds were
either analogs of known ligands (25–27, Table 3) or compounds
with novel scaffolds (24 and 28). The compounds were charac-
terized both in terms of binding affinities and binding modes.
Binding Affinities
Two different methods were used to determine binding to the
purine riboswitch in the past: in-line probing (Mandal and
Breaker, 2004) and isothermal titration calorimetry (ITC) (Gilbert
et al., 2006b). The in-line probing assay suffers from being an
indirect method whereas for the ITC assay large quantities of
RNA are required. Therefore, an alternative fluorescence assay
was developed to determine the binding affinities of the putative
ligands. Upon binding to GRA the fluorescence of 2-aminopurine
(3, Table 1) decreases (Gilbert et al., 2006a; Lemay et al., 2006).r Ltd All rights reserved
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Figure 2. Receiver Operation Characteristic
Plot for Ligands and Decoys in Database
Screen
The sensitivity (fraction of known compounds,
ligands or decoys) was plotted against 1- speci-
ficity (fraction of unassigned database com-
pounds). An AUC of 0.98 for ligands (solid lines)
and 0.75 for decoys (dotted line) was obtained.
A random prediction would result in an AUC of 0.5
(dashed line).
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was then studied as a function of the concentration of the puta-
tive ligand, using a constant concentration of 2-aminopurine and
the riboswitch (Figure 3). The ITC assay and the fluorescence
assay deliver comparable results. For 5 a binding constant of
0.020 mM was reported using the ITC assay (Gilbert et al.,
2006b) while using the fluorescence assay a binding constant
of 0.014 ± 0.001 mM was obtained. The amount of RNA used
for a fluorescence competition experiment is less than 0.5% of
that used for a typical ITC experiment.
Four out of the five chosen compounds bound to GRA with
affinities in the micromolar range (Table 3). The most potent
compound was 27 with a binding affinity of 80 mM. Addition of
a methyl group (26) did not alter the binding affinity significantly
(KD = 110 mM). When the methyl group was replaced by chlorine
(25) no binding could be detected at concentrations up to
120 mM. Both compounds containing new scaffolds (24 and
28) were weak ligands with binding affinities of 370 and 670 mM,
respectively.
Binding Modes
To determine the binding modes of the new ligands, we attemp-
ted cocrystallization with GRA. Crystallization trials with 28 led
only to microcrystals of insufficient quality for data collection.
However, high-resolution crystal structures were obtained with
compounds 24, 26, and 27 (Table 2). The crystals diffracted up
to 1.5 A˚ which is comparable to or better than previous crystal
structures (Gilbert et al., 2006a, 2006b, 2009). The overall struc-
tureof the riboswitchwasunchanged inall threecrystal structuresChemistry & Biology 18, 324–335, March 25, 2011(rmsd values <0.4 A˚ compared to 2G9C).
The ligands were clearly defined in the
Fo-Fc electron density maps (Figure 4).
Compound 24 hydrogen bonds with
the bases of U51 and U74, the ribose of
U22 and water molecule W2329 which is
located in an equivalent position to
W364 in the docking calculations (Fig-
ure 4A). The observed and the predicted
binding mode agreed within experimen-
tally error (rmsd = 0.21 A˚).
The crystal structure of GRA in
complex with 26 showed clearly defined
electron density for a ligand in the Fo-Fc
map (Figure 4B). However, due to ligand
symmetry the orientation cannot be
inferred unambiguously from the map.
Therefore, the position of water moleculeW2013 (equivalent to W364 in 2G9C) was taken into account to
model the ligand. Compared to W364, W2013 is shifted away
from the ligand by 0.75 A˚. This indicates that in the complex
with 26 a nonhydrogen bonding group occupies the space
between this water molecule and the 4-oxo group of U74.
Accordingly, the methyl group of 26 was placed into this posi-
tion. In the resulting binding mode, hydrogen bonds are formed
between the amino groups and two of the ring nitrogen atoms of
the ligand and the bases of U74 and U51 (all %2.9 A˚). The
distance from the methyl group of the ligand to W2013 is 3.3 A˚
and to the 4-oxo group of U74 is 3.1 A˚. Furthermore, a water
molecule (W2216) is found in the pocket which mediates
a contact between the ligand and the 20 hydroxyl group of U22.
This water molecule was not observed previously in any other
GRA crystal structure. The bindingmode of 26was not predicted
by the docking calculations that placed the methyl group of the
ligand close to the 4-oxo group of U51 (rmsd = 2.8 A˚). If the
shifted position of W2013 is taken into account during docking,
the correct binding mode is predicted (rmsd = 0.46 A˚).
Ligand 27 adopts two distinct binding modes in the GRA
binding site (Figure 4C). The ratio of these binding modes is
70:30 as estimated by crystallographic B-factors. In both orien-
tations the 2-amino group forms hydrogen bonds with the 2-oxo
groups of U74 and U51. In the higher populated binding mode
the 2-amino group of the ligand interacts with the 4-oxo group
of U51 and water molecule W2149 that was found in a similar
position as W2216 in the complex with 26 (Figure 4B). In the
alternative binding mode, the 4-amino group hydrogen bonds
to the 4-oxo group of U74. No significant electron density wasª2011 Elsevier Ltd All rights reserved 329
Table 3. High Scoring Compounds Selected for Experimental
Evaluation
Compound # Rank Structure KD [mM] Rmsd
a [A˚]
24 3 370 ± 40 0.21
25 7 NAb NA.
26 11 110 ± 30 0.29
27 14 80 ± 20 0.65/0.23
28 23 650 ± 180 NA
aBetween crystallographically determined binding mode and highest
scoring pose.
bNot applicable.
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multiple binding modes. The ligand could only interact with this
water molecule in one of them. In the highest scoring binding
mode the ligand orients its 4-amino group toward U51 (rmsd =
0.53 A˚). The alternative binding mode differs in score by only
1.5 kJ/mol (rmsd = 0.74 A˚).
DISCUSSION
Modeling of RNA-ligand interactions is relatively unexplored
compared to protein-ligand interactions (Fulle and Gohlke,
2010). In particular, there is a dearth of studies that make
prospective predictions that are subsequently tested in bio-
chemical assays and by structure determinations. It is often
these situations that expose the strengths and weaknesses of
the applied methods (Kolb and Irwin, 2009). In the current study,
we used a small model binding site to probe RNA-ligand dock-
ing, both retro- and prospectively. The simplicity of the GRA
binding site allowed us to separate factors that are specific
to RNA-ligand docking from more generic molecular docking
factors. Four points stand out from this study: (1) A performance
similar to protein-ligand docking was achieved using a standard
protein-ligand docking program with only minor changes. (2)330 Chemistry & Biology 18, 324–335, March 25, 2011 ª2011 ElsevieMolecular docking was able to predict new ligands, some of
them based upon scaffolds not previously known to bind to
adenine-sensing riboswitches. (3) None of the problems encoun-
tered in this study was specific to RNA-ligand docking. Instead,
well-known problems in protein-ligand docking such as the role
of water molecules, multiple binding modes and variation in
protonation states hampered the predictions. (4) GRA was
established as a model system for RNA-ligand docking allowing
both retro- and prospective predictions. An expansion of these
points follows.
We chose a docking program with a physics-based scoring
function to probe RNA-ligand docking. In theory, the use of
force-field parameters optimized for RNA atoms instead of
protein atoms should be sufficient to adapt this scoring function
for RNA-ligand docking. However, in terms of molecular recog-
nition there are two main differences between proteins and
RNA for which the scoring function might not be appropriate:
(1) RNA molecules are highly charged and (2) RNA-ligand inter-
actions are dominated by polar contacts (Hermann, 2000). We
addressed the first issue by implicitly modeling charge screening
by counter ions. The partial charges of the phosphate oxygen
atoms were modified to result in a net charge of 0 per phosphate
group as done previously (Detering and Varani, 2004; Moitessier
et al., 2006). To address the second issue, we expected
that it would be necessary to introduce correction factors to
model the balance between Evdw, Eelec, and DGsolv (Equation 1)
correctly. To our surprise, it turned out that this was not the
case. By using appropriate parameters for RNA atoms and
implicitly modeling counter ions DOCK 3.5.54 was already able
correctly to predict all known binding modes of the ligands in
the test set and to separate ligands fromdecoys (Table 1). Admit-
tedly, only moderate correlation between binding affinities and
docking scores was obtained. While this is unsatisfactory it is
comparablewith the performance of protein-ligand scoring func-
tions commonly used for virtual screening (Li et al., 2010a). When
docking a large database into the GRA binding site almost
perfect discrimination between known ligands and database
compounds was obtained (AUC of the ROC curve = 0.98, Fig-
ure 3). This is comparable or better to that obtained in protein-
ligand docking studies with binding sites of similar complexity
as the GRA binding site (Wei et al., 2002; Brenk et al., 2006).
Collectively, the retrospective docking results demonstrated
that RNA-ligand docking with the chosen parameterization
performs well for the GRA binding site. The terms in the
physics-based scoring function were well balanced and no addi-
tional corrections were necessary in order to apply DOCK 3.5.54
to RNA-ligand docking.
Five high scoring compounds were selected for prospective
tests. Four of them were shown experimentally to bind to GRA
(Table 3). The most potent of these ligands was 27. The binding
affinity of this compound (KD = 80 mM) was only 4-fold lower than
that of the related ligand 2 (Table 1). Weaker binding probably
arose from the lack of an amino group resulting in fewer
hydrogen bonds between ligand and GRA (Figure 4C). In 26,
one of the amino groups of 2 is replaced by methyl. Thus, 26
not only forms fewer hydrogen bonds in the binding site than 2
but in addition the hydrophobic methyl group does not satisfy
hydrogen-bonding interactions with surrounding polar groups
(Figure 4B). Despite these unfavorable contacts, the bindingr Ltd All rights reserved
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Figure 3. Plot of Fraction of Free 2-Amino-
purine against Varying Concentrations of
Compound 27
The data were fitted to a one binding site model
with two equilibria. Three titrations are shown
together with the resulting fit.
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Purine Riboswitch Ligands Discovered by Dockingaffinity of 26was only slightly lower (KD = 110 mM) than that of 27.
When the methyl group of 26 was replaced by a chlorine atom,
binding was diminished (25, Table 3) There are two probable
reasons: (1) If 25 were bound to the receptor in a similar binding
mode as 26 or 27, the potential locations for the chlorine
atom would result in close contacts to oxo groups from the
surrounding bases. However, the resulting directionality would
not satisfy the angular requirements for a C-Cl,,,O interaction,
generating repulsion (Bissantz et al., 2010). (2) Due to inductive
effects the ring nitrogen atoms of 25 are less basic than those
of 26, leading to weaker hydrogen bonds in the orientation
required for riboswitch binding. Obviously, the scoring function
was not able to reproduce these effects. Compounds 24 and
28 are both based upon scaffolds that were not previously
observed to bind to adenine-sensing riboswitches. With binding
affinities of 370 and 650 mM, they are rather weak ligands. The
thiadiazole derivative 28 is the smallest GRA or AR ligand known
to date. Due to its small size it has only limited shape comple-
mentarity with the binding site, which might lead to weak binding
properties. Superimposing the binding modes of the ligands 2
and 24 reveals that both compounds have a similar arrangement
of hydrogen-bond donor and acceptor groups with respect to
U51 and U47 (Figure 4D). However, 24 forms an additional
hydrogen bond to the ribose of U47 but is in turn lacking
a hydrogen-bond donor group to interact with the 4-oxo group
of the base of U74. The difference in the binding affinities of
2,6-diaminopurine (1) and 2-aminopurine (3) suggests that the
formation of the hydrogen bond to U74 can lead to a 30-fold
improvement in binding affinity (Table 1) (Gilbert et al., 2006b).
Apparently, the additional hydrogen bond formed by 24 with
the ribose can not compensate for the loss of this important
hydrogen bond. The small size of the GRA binding site combined
with the high density of hydrogen-bond donor and acceptor
groups leaves little opportunity to derive tightly-binding scaffolds
other than purine. Nevertheless, retrieving the ligands 24 and 28
underlines the power of molecular docking to discover hits that
are structurally unrelated to known ligands. In previous studiesChemistry & Biology 18, 324–335, March 25, 2011with purine riboswitches, ligands that
closely resembled the natural ligands
were designed (Kim et al., 2009; Mulh-
bacher et al., 2010). Clearly, RNA-ligand
docking has the potential to exploit the
wealth of riboswitch crystal structures to
derive ligands that go beyond such close
modifications.
The problems that were encountered in
this docking study were not specific to
RNA docking. Deficiencies of treating
structural water molecules hampered
the prediction of the binding modes of14 and 26 and the ranking of 14 (Figure 1 and Table 1). This is
a well-known problem in molecular docking (Schneider, 2010)
and progress has beenmade to solve it in recent years (Mancera,
2007). However, commonly used scoring functions are still not
able to treat displaceable water molecules reliably (Englebienne
and Moitessier, 2009). Decoy 6 obtained a score that was too
favorable because it was stored as a neutral molecule in the
database whereas the compound is likely to be predominantly
deprotonated under assay conditions. We used a rule-based
approach to generate protonation states and tautomers for the
docking database (Mpamhanga et al., 2009). While this is very
fast, it has the drawback that the approach is not generic.
Compounds containing patterns for which no rules have been
defined will necessarily fail as it was the case with 6 in this study.
More sophisticated computational methods for pKa prediction
are available (Liao and Nicklaus, 2009; Manchester et al., 2010)
and can be used for database preparation (Kalliokoski et al.,
2009). The challenge will be to correctly model pKa shifts upon
ligand binding (Klebe, 2006). Finally, ligand 27 adopts two
distinct binding modes when bound to GRA (Figure 4C).
Routinely, molecular docking predicts only one binding mode
for each ligand. However, multiple binding modes are frequently
observed in crystal structures. Computational methods that
take these into account have recently been developed but not
yet tested on a larger scale (Gorelik and Goldblum, 2008; Stjern-
schantz and Oostenbrink, 2010). Improved algorithms and
scoring functions addressing any issues discussed above will
not only improve RNA-ligand docking, but molecular docking
in general.
We established the GRA as a model system for RNA-ligand
docking studies. A set of known ligands and decoys together
with high-resolution crystal structures is a valuable data source
for retrospective testing of docking algorithms and scoring func-
tions. Due to the small size and low complexity of the binding
pocket it is possible to identify why incorrect predictions have
been made, that in turn can suggest directions for future
improvements. The competition binding assay (Figure 3) allowsª2011 Elsevier Ltd All rights reserved 331
Figure 4. Crystallographically Determined Binding Modes for Ligands Identified by Molecular Docking
Crystallographically determined binding modes of 24 (A), 26 (B), and 27 (C) together with Fo-Fcmap (contoured on 2.5 s for A and C and 3.0s for B) which was
calculated by omitting the ligands and water molecules from the final model. Putative hydrogen bonds are marked as dashed lines. In (B), the position of W364
from 2G9C is marked as green sphere. (D) Superposition of crystallographically determined binding modes of 2 (blue carbon atoms, water molecule W364
indicated as blue sphere) and 24 (green carbon atoms, water molecule W2329 indicated as green sphere). Hydrogen bonds are marked as dashed lines in red for
2 and black for 24.
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Purine Riboswitch Ligands Discovered by Dockingdetermination of binding affinities of predicted ligands in a less
time- and RNA-consuming way than in-line probing and
ITC assays used previously (Mandal and Breaker, 2004;
Gilbert et al., 2006b). Crystallizing GRA is straightforward and
complexes with soluble ligands can be obtained routinely to
verify predicted binding modes. In the current study, we consid-
ered the GRA binding site to be rigid. Recently determined
crystal structure complexes with the related guanine riboswitch
revealed that the base in position 74 adopts different conforma-
tions depending on the bound ligand, suggesting a degree of
induced fit (Gilbert et al., 2009). In ongoing work, we are using
this information to study how RNA flexibility can be modeled in
RNA-ligand docking.
In summary, GRA is a valuable model system for studying
RNA-ligand docking, both retro- and prospectively. Using a
standard protein-ligand docking program with only minor modi-332 Chemistry & Biology 18, 324–335, March 25, 2011 ª2011 Elseviefications, new ligands, including some which are structural
distinct from known ligands, were identified. Due to the
limited size of the GRA binding pocket with a high density of
hydrogen-bond donor and acceptor groups modifications of
the ligand scaffold lead to compromised hydrogen-bonding
capabilities which are associated with a drop in binding affinity.
Nevertheless, the current study demonstrated that molecular
docking is a promising tool for the discovery of structural diverse
RNA ligands.
SIGNIFICANCE
Protein-ligand docking is an important tool in structure-
based drug design. However, despite the structural knowl-
edge of RNA targets, RNA-ligand docking is still in its infancy
limiting the drug discovery process for this class of targets.r Ltd All rights reserved
Chemistry & Biology
Purine Riboswitch Ligands Discovered by DockingUsing a purine riboswitch as a model system, we demon-
strate that RNA-ligand docking is performing comparably
to protein-ligand docking. Furthermore, we show that
using this method ligands based on novel molecular scaf-
foldscanbe identifiedmakingRNA-liganddocking asuitable
tool to explore the wealth of RNA crystal structures for the
discovery of new ligands.
EXPERIMENTAL PROCEDURES
Receptor Preparation
GRA (PDB code 2G9C) was used for docking. Hydrogen atoms were added
using Sybyl (Tripos). The positions of the hydrogen atoms were minimized
using the MAB force field as implemented in Moloc (Gerber Molecular Design)
(Gerber and Muller, 1995) while keeping all other atoms rigid. Afterward, all
atoms not part of the RNA except of water molecule W364 were removed.
To define the ligand binding site a cubic grid was placed 2 A˚ around the ligand
with a grid width of 1.5 A˚. Spheres were placed on all grid points not overlap-
ping with the receptor. Partial charges for all RNA atoms except of phosphate
oxygen atoms were obtained from the AMBER99 force-field parameter (Wang
et al., 2000). The phosphate oxygen atoms were assigned a partial charge
higher than the charge stored in the AMBER database to obtain a net charge
of zero per nucleotide, thus mimicking charge screening by nonspecific
binding of counter ions (Detering and Varani, 2004; Moitessier et al., 2006).
Grids to store information about excluded volumes, electrostatic and van
der Waals potential, and solvent occlusion were calculated as described
earlier (Brenk et al., 2006).
Preparation of Small Molecules for Docking
Protonation states, tautomers, partial charges, desolvation energies, and low-
energy conformations were calculated as described earlier (Mpamhanga et al.,
2009).
For the screening, database compounds were selected from our in-house
database containing commercially available compounds (Brenk et al., 2008).
All molecules fulfilling the selection criteria were subsequently docked into
the riboswitch binding site and only compounds that gave a negative van
der Waals energy score were retained for the final docking database and
analysis.
Where needed, pKa values were calculated using Marvin (Chemaxon) with
default settings.
Molecular Docking
DOCK 3.5.54 was used to dock small molecules into the GRA binding pocket
(Lorber and Shoichet, 1998; Wei et al., 2002). Ligand orientations were
sampled using the following settings: ligand and receptor bins were set to
0.5 A˚, overlap bins were set to 0.4 A˚, and the distance tolerance for matching
ligand atoms to receptor matching sites ranged from 1.1 to 1.2 A˚. Each dock-
ing pose that did not place any atoms in areas occupied by the receptor was
scored for electrostatic and van der Waals complementarity (Wei et al., 2002)
and penalized according to its estimated partial desolvation energy (B. Shoi-
chet, unpublished). For each compound, only the best-scoring database
representation (tautomer, protonation state, multiple ring alignment) was
stored in the final docking hit list. Rmsds between docked and crystallograph-
ically determined binding modes were calculated after superimposing the N3
atoms of U22, 47, 51, and 74 of the crystal structures onto the receptor used
for docking.
RNA Preparation and Purification
RNA was prepared and purified as described (Gilbert et al., 2006a).
Ligand-Binding Assay
All compounds for binding studies were purchased from Sigma Aldrich with
the following exceptions: 24was obtained from IBS and 28was fromChemdiv.
Fluorescence spectra were recorded using an SLM-Aminco 8100 fluorim-
eter. The sample buffer contained 50 mM Tris-HCl (pH 8.3), 100 mM KCl,
and 10 mM MgCl2. 2-Aminopurine (3) spectra were recorded from 330 to
450 nm with an excitation wavelength of 300 nm. The data were correctedChemistry & Biology 18, 3for lamp fluctuations and instrumental variations. The spectra were integrated
to determine the total amount of 2-aminopurine fluorescence.
The binding constant of 3 was determined by titrating RNA into a solution
containing 200 nM of that compound. After each addition of RNA 3 min were
allowed to reach equilibrium. Free 2-aminopurine fluorescence was fitted to
a simple binding model. A binding constant of KL = 140 nM was obtained.
Competition experiments were carried out by titrating the competition ligand
into a solution containing 3 and GRA. A 2-aminopurine spectrum in fluores-
cence buffer (typically 213 nM) was recorded. GRA was added to a final
concentration of 243 nM resulting in 200 nM 2-aminopurine concentration
and left to equilibrate for 10 min. Subsequently, the competition ligand was
incrementally added to a final concentration of at least 1.2 mM, except for
28 that was titrated to 0.68mM and 25 to 0.12mM due to lower solubility. After
each addition of ligand 3 min were allowed for equilibration. Data were pro-
cessed using Microsoft Excel. Free 2-aminopurine fluorescence was fitted
to a two complex binding model (Equation 2) with dilution effects were taken
into account (Yan et al., 2005).
R3 + aR2 +bR KLKDRtot = 0; (2)
where
a= Ltot +Xtot +KL +KD  Rtot
b=KDLtot +KLXtot +KLKD  RtotðKL +KDÞ
In these equations, R is the concentration of unbound RNA; Rtot the total RNA
concentration; Ltot the total 2-aminopurine concentration; Xtot the total
concentration of test compound; KL the dissociation constant of 2-aminopur-
ine; and KD the dissociation constant of the test compound. All parameters
except R and KD are known. R was obtained from the fluorescence
reading using the known KL. Experimental error will result in R
3 + aR2 +
bR KLKXRtot =c for each data point. Fitting was performed by minimizing
F=Sc2 through varying KD. The obtained binding constants were rounded
to a precision of 0.01 mM (0.001 mM in the case of 5). The reported binding
constants are the average of three measurements.Structure Determination
RNA-ligand complexes were crystallized using micro seeding as described
earlier. (Batey et al., 2004) For data collection crystals were cryoprotected
using the respective well solution with 30%MPD. Cryoprotectant was applied
for approximately oneminute before freezing in liquid nitrogen. Diffraction data
for 14 was collected at Diamond Light Source (Oxford, UK), beamline I03. All
other data were collected at beamline ID14-1 at the European Synchrotron
Radiation Facility (ESRF) in Grenoble, France. Data were indexed, integrated
and scaled using HKL2000 (Otwinowski and Minor, 1997). The structures
were solved using MOLREP (Vagin and Teplyakov, 1997) using 2G9C as start-
ing model and refined with REFMAC5 (Vagin et al., 2004) via the CCP4 suite of
programs (CCP4, 1994). Ligand topology files were generated using the
PRODRG server (Schuttelkopf and van Aalten, 2004). Model building was
carried out using COOT (Emsley and Cowtan, 2004).ACCESSION NUMBERS
Coordinates have been deposited in the PDB with accession codes 2xo1,
2nxw, 2nxz, and 2xo0.ACKNOWLEDGMENTS
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